Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Small Cell Lung Carcinoma 2Lung Neoplasms 2Neuroendocrine Prostate Cancer 1Extensive Stage Small Cell Lung Cancer 1Bites and Stings 1

Interventions

Radiotherapy 38Carboplatin 37pembrolizumab 36Cisplatin 34Paclitaxel 26Pemetrexed 24Docetaxel 18Nivolumab 17Gemcitabine 17Bevacizumab 17Specimen Handling 16Magnetic Resonance Spectroscopy 16Cyclophosphamide 15osimertinib 14Irinotecan 13Etoposide 13Radiation 12Erlotinib Hydrochloride 12durvalumab 11Topotecan 10Cetuximab 10Radiosurgery 8Immunoglobulin G 8Fluorouracil 8Everolimus 8Disulfides 8Celecoxib 8fludarabine 7Taxes 7Ipilimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Lung Neoplasms × AMG 757 × Clear all
NCT05361395 2026-03-03

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Amgen

Phase 1 Active not recruiting
184 enrolled
Thoracic

Bites and Stings, Lung Neoplasms

NCT04885998 2025-09-29

AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)

Amgen

Phase 1 Completed
23 enrolled 21 charts
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡